Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.55 |
| ▸ | CTSG | P08311 | 3/20 | 0.55 |
| ▸ | PRTN3 | P24158 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethadione SCHEMBL13724326 | 0.90 | LMNA (0.70) | ELANECTSGPRTN3LMNAF2 | |
| SCHEMBL14009928 | 0.83 | LMNA (0.54) | ELANECTSGPRTN3LMNAPGR | |
| SCHEMBL4757301 | 0.80 | ELANE (0.53) | ELANECTSGPRTN3LMNAPGR | |
| SCHEMBL7309157 | 0.80 | ELANE (0.53) | ELANECTSGPRTN3LMNAPGR | |
| SCHEMBL24220557 | 0.80 | ELANE (0.53) | ELANECTSGPRTN3LMNAPGR | |
| SCHEMBL14009929 | 0.79 | LMNA (0.50) | ELANECTSGPRTN3LMNAALDH1A1 | |
| SCHEMBL13188868 | 0.77 | LMNA (0.52) | ELANECTSGPRTN3LMNAAR | |
| SCHEMBL4755116 | 0.77 | ELANE (0.50) | ELANECTSGPRTN3LMNAAR | |
| SCHEMBL5006337 | 0.77 | ELANE (0.54) | ELANECTSGPRTN3LMNAAR | |
| SCHEMBL13622590 | 0.77 | ELANE (0.50) | ELANECTSGPRTN3LMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1830 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| WO-2024028611-A1 | OXADIAZOLE COMPOUNDS FOR USE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | SIRGARTAN HOLDINGS LTD (GB) | 2024-02-08 | — | — | WO | claimed |
| US-11786487-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-10-17 | — | — | US | claimed |
| WO-2023178250-A1 | TREATMENT OF TUBEROUS SCLEROSIS WITH MIRDAMETINIB | SpringWorks Therapeutics Inc. (US) | 2023-09-21 | — | — | WO | claimed |
| US-11759440-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-09-19 | — | — | US | claimed |
| CN-110658337-B | Diagnosis and treatment of autoimmune diseases | 武田药品工业株式会社 | 2023-06-16 | — | — | CN | claimed |
| CN-110208533-B | Evaluation, determination and treatment of PKAL-mediated disorders | 武田药品工业株式会社 | 2023-01-10 | — | — | CN | claimed |
| US-20210393550-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-12-23 | — | — | US | claimed |
| US-11040018-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-06-22 | — | — | US | claimed |
| WO-2021060998-A1 | PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY, AND THE USE OF J05 ATC GROUP SUBSTANCES IN TREATMENT OF NERVOUS TISSUE DYSFUNCTION, IN PARTICULAR VIRAL LATENCY | CHUPTYŚ CONTISSI, Janusz (PL) | 2021-04-01 | — | — | WO | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20050070524-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
| WO-2005000294-A1 | SELECTIVE INHIBITOR AND AN ANTICONVULSANT AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0942752-A1 | ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN | Algos Pharmaceutical Corporation (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998007447-A1 | ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-02-26 | — | — | WO | claimed |
| US-4374953-A | Method for preparing polyacetals and polyketals by emulsion polymerization | DOW CORNING CORPORATION (US) | 1983-02-22 | — | — | US | claimed |
| US-4160818-A | Fluorimetric immunoassay for diphenylhydantoin | TECHNICON INSTRUMENTS CORPORATION (US) | 1979-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040018-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | HTR2B, HTR1B, CYP4B1 | ELANE 4699/4885CTSG 1837/4885PRTN3 4223/4885 |
| US-11759440-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | HTR2B, HTR1B, CYP4B1 | ELANE 4699/4885CTSG 1837/4885PRTN3 4223/4885 |
| US-11786487-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | HTR2B, HTR1B, CYP4B1 | ELANE 4699/4885CTSG 1837/4885PRTN3 4223/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | ELANE 387/4885CTSG 536/4885PRTN3 545/4885 |
| US-20050070524-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders | PTGS2, PTGER2, PTGES2 | ELANE 1599/4885CTSG 1109/4885PRTN3 719/4885 |
| US-20210393550-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | HTR2B, HTR1B, CYP4B1 | ELANE 4699/4885CTSG 1837/4885PRTN3 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.